Emtricitabine/tenofovir (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Emtricitabine/tenofovir" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
11th place
8th place
102nd place
76th place
3,912th place
2,496th place
low place
low place
266th place
182nd place
34th place
27th place
3,984th place
2,622nd place
3,823rd place
2,387th place
36th place
33rd place
5th place
5th place
907th place
580th place
3,771st place
2,605th place
3,258th place
2,666th place
low place
low place
800th place
676th place
low place
8,921st place
low place
low place
8,255th place
low place
low place
low place
8,771st place
5,253rd place
low place
low place
low place
low place
low place
low place
aasld.org
- "Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance" (PDF). Archived from the original (PDF) on 25 January 2020. Retrieved 20 November 2019.
aidsmap.com
- "PrEP does not raise lipids or alter body fat, safety study finds". Retrieved 16 February 2018.
- "European PrEP programs face two big issues: How to get more people coming forward, and how to serve them if they do". 27 January 2021.
cdc.gov
cdc.gov
- "PrEP". Centers for Disease Control and Prevention (CDC). 17 October 2019. Archived from the original on 31 October 2019. Retrieved 31 October 2019.
This article incorporates text from this source, which is in the public domain. - "Pre-Exposure Prophylaxis (PrEP)". Archived from the original on 5 June 2015. Retrieved 4 June 2015. This article incorporates text from this source, which is in the public domain.
- Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS (September 2005). "Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis" (PDF). MMWR Recomm Rep. 54 (RR-9): 1–17. PMID 16195697.
stacks.cdc.gov
- Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis" (PDF). Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. PMID 23917901. S2CID 17032413. 20711. This article incorporates text from this source, which is in the public domain.
clincalc.com
- "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- "Emtricitabine; Tenofovir Disoproxil - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
cms.gov
- "FAQS ABOUT AFFORDABLE CARE ACT IMPLEMENTATION PART 47" (PDF). Centers for Medicare & Medicaid Services. 19 July 2021. Retrieved 4 August 2022.
doi.org
- Okwundu CI, Uthman OA, Okoromah CA (2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". Cochrane Database Syst Rev. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505. S2CID 35672491.
- Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (11 June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. ISSN 0098-7484. PMID 31184746. S2CID 184485546.
- Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis" (PDF). Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. PMID 23917901. S2CID 17032413. 20711. This article incorporates text from this source, which is in the public domain.
- Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. (July 2018). "Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine". Clin. Infect. Dis. 67 (3): 411–419. doi:10.1093/cid/ciy083. PMC 6051460. PMID 29415175.
- Lay summary in: "Truvada as HIV PrEP not associated with net fat increase". Healio. 13 February 2018.
- Ramanathan S, Shen G, Cheng A, Kearney BP (July 2007). "Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137". J. Acquir. Immune Defic. Syndr. 45 (3): 274–9. doi:10.1097/QAI.0b013e318050d88c. PMID 17414929. S2CID 31756102.
- Keith K (2021). "New Guidance On PrEP: Support Services Must Be Covered Without Cost-Sharing | Health Affairs Forefront". Health Affairs Forefront. doi:10.1377/forefront.20210728.333084. Retrieved 4 August 2022.
drugs.com
- "Emtricitabine / tenofovir Pregnancy and Breastfeeding Warnings". Drugs.com. 1 August 2018. Archived from the original on 10 October 2019. Retrieved 10 October 2019.
- "Truvada". Drugs.com. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- "Emtricitabine and Tenofovir Disoproxil Fumarate (Professional Patient Advice)". Drugs.com. Retrieved 31 October 2019.
- "Emtricitabine / tenofovir Use During Pregnancy". Drugs.com. Retrieved 23 October 2019.
espacenet.com
worldwide.espacenet.com
- "EP0915894B1 - NUCLEOTIDE ANALOGS". Espacenet. Retrieved 13 December 2017.
europa.eu
ema.europa.eu
- "Truvada EPAR". European Medicines Agency. 21 February 2005. Retrieved 13 June 2024.
fda.gov
nctr-crs.fda.gov
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
fiercepharma.com
gilead.com
- "Petitions to US Patent and Trademark Office on HIV PrEP Patents". Gilead Sciences (Press release). 21 August 2019. Archived from the original on 30 October 2019. Retrieved 29 October 2019.
handle.net
hdl.handle.net
- World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
healio.com
- Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. (July 2018). "Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine". Clin. Infect. Dis. 67 (3): 411–419. doi:10.1093/cid/ciy083. PMC 6051460. PMID 29415175.
- Lay summary in: "Truvada as HIV PrEP not associated with net fat increase". Healio. 13 February 2018.
healthaffairs.org
- Keith K (2021). "New Guidance On PrEP: Support Services Must Be Covered Without Cost-Sharing | Health Affairs Forefront". Health Affairs Forefront. doi:10.1377/forefront.20210728.333084. Retrieved 4 August 2022.
independent.co.uk
- "AOC asks pharma CEO why $2,000 HIV drug costs just $8 in Australia". The Independent. 17 May 2019. Retrieved 15 November 2019.
irishtimes.com
- "Gilead loss of generic HIV drug battle a boost for gay community". The Irish Times. Retrieved 18 May 2018.
- "Gilead in row with generics manufacturers over HIV drug in Ireland". The Irish Times. Retrieved 30 October 2017.
iwantprepnow.co.uk
medicalxpress.com
medicines.org.uk
- "UK label Truvada film-coated tablets". Electronic Medicines Compendium. August 2016. Archived from the original on 20 December 2016.
nice.org.uk
nih.gov
pubmed.ncbi.nlm.nih.gov
- Okwundu CI, Uthman OA, Okoromah CA (2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". Cochrane Database Syst Rev. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505. S2CID 35672491.
- Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (11 June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. ISSN 0098-7484. PMID 31184746. S2CID 184485546.
- Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS (September 2005). "Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis" (PDF). MMWR Recomm Rep. 54 (RR-9): 1–17. PMID 16195697.
- Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis" (PDF). Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. PMID 23917901. S2CID 17032413. 20711. This article incorporates text from this source, which is in the public domain.
- "Tenofovir". Drugs and Lactation Database (LactMed). National Library of Medicine (US). 2006. PMID 30000609. Retrieved 23 October 2019.
- Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. (July 2018). "Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine". Clin. Infect. Dis. 67 (3): 411–419. doi:10.1093/cid/ciy083. PMC 6051460. PMID 29415175.
- Lay summary in: "Truvada as HIV PrEP not associated with net fat increase". Healio. 13 February 2018.
- Ramanathan S, Shen G, Cheng A, Kearney BP (July 2007). "Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137". J. Acquir. Immune Defic. Syndr. 45 (3): 274–9. doi:10.1097/QAI.0b013e318050d88c. PMID 17414929. S2CID 31756102.
aidsinfo.nih.gov
- "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV" (PDF). AIDSinfo Clinical Guidelines. July 2019. Archived from the original (PDF) on 4 December 2016. Retrieved 30 October 2019.
- "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV" (PDF). Archived from the original (PDF) on 4 December 2016. Retrieved 30 October 2019.
- "Brief What's New in the Guidelines Perinatal". AIDSinfo. Archived from the original on 23 October 2019. Retrieved 23 October 2019.
- "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States" (PDF). National Institutes of Health (NIH). Archived (PDF) from the original on 12 April 2014. Retrieved 21 October 2014.
ncbi.nlm.nih.gov
- Okwundu CI, Uthman OA, Okoromah CA (2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". Cochrane Database Syst Rev. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505. S2CID 35672491.
- "Tenofovir". Drugs and Lactation Database (LactMed). National Library of Medicine (US). 2006. PMID 30000609. Retrieved 23 October 2019.
- Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. (July 2018). "Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine". Clin. Infect. Dis. 67 (3): 411–419. doi:10.1093/cid/ciy083. PMC 6051460. PMID 29415175.
- Lay summary in: "Truvada as HIV PrEP not associated with net fat increase". Healio. 13 February 2018.
dailymed.nlm.nih.gov
- "Truvada- emtricitabine and tenofovir disoproxil fumarate tablet, film coated label". DailyMed. 18 May 2018. Archived from the original on 31 October 2019. Retrieved 31 October 2019.
- "DailyMed - XENICAL- orlistat capsule". dailymed.nlm.nih.gov. Retrieved 30 October 2019.
nwsource.com
seattletimes.nwsource.com
- Perrone M (16 July 2012). "FDA approves first pill to help prevent HIV". The Seattle Times. Associated Press. Archived from the original on 19 July 2012.
pharmacy-xl.org
pharmaphorum.com
- "Truvada ruling could allow cheap HIV prevention in the UK -". 19 September 2018.
semanticscholar.org
api.semanticscholar.org
- Okwundu CI, Uthman OA, Okoromah CA (2012). "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals". Cochrane Database Syst Rev. 7 (7): CD007189. doi:10.1002/14651858.CD007189.pub3. PMC 11324012. PMID 22786505. S2CID 35672491.
- Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (11 June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. ISSN 0098-7484. PMID 31184746. S2CID 184485546.
- Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. (September 2013). "Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis" (PDF). Infection Control and Hospital Epidemiology. 34 (9): 875–92. doi:10.1086/672271. PMID 23917901. S2CID 17032413. 20711. This article incorporates text from this source, which is in the public domain.
- Ramanathan S, Shen G, Cheng A, Kearney BP (July 2007). "Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137". J. Acquir. Immune Defic. Syndr. 45 (3): 274–9. doi:10.1097/QAI.0b013e318050d88c. PMID 17414929. S2CID 31756102.
statnews.com
- Silverman E (8 July 2024). "Biden administration appeals jury finding in battle over patents for HIV prevention pills". STAT News. Retrieved 8 July 2024.
tga.gov.au
- "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
uptodate.com
- "Administration of pre-exposure prophylaxis against HIV infection". UpToDate. Archived from the original on 1 November 2019. Retrieved 31 October 2019.
washingtonpost.com
- Rowland C (24 April 2019). "Gilead defied a government HIV patent. The Justice Department has opened a review". The Washington Post. Archived from the original on 1 November 2019. Retrieved 31 October 2019.
- Rowland C (21 August 2019). "Gilead files challenge to government patents for HIV prevention pill". The Washington Post. Archived from the original on 1 November 2019. Retrieved 29 October 2019.
web.archive.org
- "Emtricitabine / tenofovir Pregnancy and Breastfeeding Warnings". Drugs.com. 1 August 2018. Archived from the original on 10 October 2019. Retrieved 10 October 2019.
- "Truvada". Drugs.com. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- "UK label Truvada film-coated tablets". Electronic Medicines Compendium. August 2016. Archived from the original on 20 December 2016.
- "Truvada- emtricitabine and tenofovir disoproxil fumarate tablet, film coated label". DailyMed. 18 May 2018. Archived from the original on 31 October 2019. Retrieved 31 October 2019.
- "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV" (PDF). AIDSinfo Clinical Guidelines. July 2019. Archived from the original (PDF) on 4 December 2016. Retrieved 30 October 2019.
- "PrEP". Centers for Disease Control and Prevention (CDC). 17 October 2019. Archived from the original on 31 October 2019. Retrieved 31 October 2019. This article incorporates text from this source, which is in the public domain.
- Perrone M (16 July 2012). "FDA approves first pill to help prevent HIV". The Seattle Times. Associated Press. Archived from the original on 19 July 2012.
- "Pre-Exposure Prophylaxis (PrEP)". Archived from the original on 5 June 2015. Retrieved 4 June 2015. This article incorporates text from this source, which is in the public domain.
- "Administration of pre-exposure prophylaxis against HIV infection". UpToDate. Archived from the original on 1 November 2019. Retrieved 31 October 2019.
- "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV" (PDF). Archived from the original (PDF) on 4 December 2016. Retrieved 30 October 2019.
- "Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance" (PDF). Archived from the original (PDF) on 25 January 2020. Retrieved 20 November 2019.
- "Brief What's New in the Guidelines Perinatal". AIDSinfo. Archived from the original on 23 October 2019. Retrieved 23 October 2019.
- "Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States" (PDF). National Institutes of Health (NIH). Archived (PDF) from the original on 12 April 2014. Retrieved 21 October 2014.
- Rowland C (24 April 2019). "Gilead defied a government HIV patent. The Justice Department has opened a review". The Washington Post. Archived from the original on 1 November 2019. Retrieved 31 October 2019.
- Rowland C (21 August 2019). "Gilead files challenge to government patents for HIV prevention pill". The Washington Post. Archived from the original on 1 November 2019. Retrieved 29 October 2019.
- "Petitions to US Patent and Trademark Office on HIV PrEP Patents". Gilead Sciences (Press release). 21 August 2019. Archived from the original on 30 October 2019. Retrieved 29 October 2019.
worldcat.org
search.worldcat.org
- Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. (11 June 2019). "Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 321 (22): 2214–2230. doi:10.1001/jama.2019.2591. ISSN 0098-7484. PMID 31184746. S2CID 184485546.